drugset
drugset / Trial / NCT00738764

A Trial of PDL192 in Subjects With Advanced Solid Tumors

NCT00738764 ↗

Phase 1 Completed 30 enrolled Abbott
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a phase 1, multicenter, open-label, dose escalation trial of PDL192 in subjects with advanced solid tumors.

Timeline

Start
2008-07
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ENAVATUZUMAB Monoclonal antibody — —

Indications

cancer